ArticleMicrobial ecology2017
Reducing the Bottleneck in Discovery of Novel Antibiotics.
Article in Microbial ecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Beyond traditional screening: Unveiling antibiotic potentials of actinomycetes in extreme environments.Heliyon · 2024Article
- Perturbation-specific transcriptional mapping for unbiased target elucidation of antibiotics.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Phage Digestion of a Bacterial Capsule Imparts Resistance to Two Antibiotic Agents.Microorganisms · 2021Article
- Predicting antimicrobial mechanism-of-action from transcriptomes: A generalizable explainable artificial intelligence approach.PLoS computational biology · 2021Article
- Chemotranscriptomic Profiling Defines Drug-Specific Signatures of the Glycopeptide Antibiotics Dalbavancin, Vancomycin and Chlorobiphenyl-Vancomycin in a VanB-Type-Resistant Streptomycete.Frontiers in microbiology · 2021Article
- Omics for Bioprospecting and Drug Discovery from Bacteria and Microalgae.Antibiotics (Basel, Switzerland) · 2020Review
- Antibacterial Discovery: 21st Century Challenges.Antibiotics (Basel, Switzerland) · 2020Article
- Mechanism-of-Action Classification of Antibiotics by Global Transcriptome Profiling.Antimicrobial agents and chemotherapy · 2020Article
- Cooperative Involvement of Glycosyltransferases in the Transfer of Amino Sugars during the Biosynthesis of the Macrolactam Sipanmycin by Streptomyces sp. Strain CS149.Applied and environmental microbiology · 2018Article
- Secondary Metabolites of Mangrove-Associated Strains of Talaromyces.Marine drugs · 2018Review
- Searching for Glycosylated Natural Products in Actinomycetes and Identification of Novel Macrolactams and Angucyclines.Frontiers in microbiology · 2018Article
- The Threat of Antimicrobial Resistance on the Human Microbiome.Microbial ecology · 2017Review
- Role of GntR Family Regulatory GeneBioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Most antibiotics were discovered by screening soil actinomycetes, but the efficiency of the discovery platform collapsed in the 1960s. By now, more than 3000 antibiotics have been described and most of the current discovery effort is focused on the rediscovery of known compounds, making the approach impractical. The last marketed broad-spectrum antibiotics discovered were daptomycin, linezolid, and fidaxomicin. The current state of the art in the development of new anti-infectives is a non-existent pipeline in the absence of a discovery platform. This is particularly troubling given the emergence of pan-resistant pathogens. The current practice in dealing with the problem of the background of known compounds is to use chemical dereplication of extracts to assess the relative novelty of a compound it contains. Dereplication typically requires scale-up, extraction, and often fractionation before an accurate mass and structure can be produced by MS analysis in combination with 2D NMR. Here, we describe a transcriptome analysis approach using RNA sequencing (RNASeq) to identify promising novel antimicrobial compounds from microbial extracts. Our pipeline permits identification of antimicrobial compounds that produce distinct transcription profiles using unfractionated cell extracts. This efficient pipeline will eliminate the requirement for purification and structure determination of compounds from extracts and will facilitate high-throughput screen of cell extracts for identification of novel compounds.
Indexed as
Identifiers
27896376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.